Navigating the Complex Treatment Landscape in Relapsed/Refractory Myeloma

Download All
Review the latest evidence-based strategies on individualized treatment of relapsed/refractory multiple myeloma with downloadable slides, a podcast, and an on-demand webcast from a live CCO webinar.
Paul G. Richardson, MD
Program Director
Natalie S. Callander, MD
Noopur Raje, MD
Paul G. Richardson, MD

Downloadable Slidesets

Download these expert-selected slides on current best practices for later-stage relapsed/refractory multiple myeloma and investigational agents in this setting.

Paul G. Richardson, MD Released: September 22, 2022

Download these expert-selected slides on current best practices for early stage relapsed/refractory multiple myeloma to help diagnose and manage your patients.

Natalie S. Callander, MD Released: September 22, 2022

Download these expert-selected slides on current and investigational anti-BCMA CAR T-cell and bispecific therapies for relapsed/refractory multiple myeloma.

Noopur Raje, MD Released: September 22, 2022

Download this short summary slideset of key takeaways from a live webinar on best practices with treatment selection for patients with relapsed/refractory multiple myeloma.

Natalie S. Callander, MD Noopur Raje, MD Paul G. Richardson, MD Released: September 22, 2022

On-Demand Webcast

In this on-demand webcast from a live webinar, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, discuss recent advances in new and emerging therapies for patients with relapsed/refractory multiple myeloma.

Paul G. Richardson, MD
Program Director
Natalie S. Callander, MD Noopur Raje, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 16, 2022 Expired: September 15, 2023
Provided by Medical Learning Institute, Inc. in partnership with Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Karyopharm Therapeutics Inc.
Regeneron Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings